Identifying Novel Drug Treatment Options for Pediatric Osteosarcoma
Files
Download Transcript, Episode 129 (84 KB)
Loading...
Document Type
Podcast
Hosts
Michael Smith
Featured Speaker
Tomoo Iwakuma, MD, PhD
Length of Episode
13:17
Description
Osteosarcoma is highly metastatic and drug-resistant cancer. The survival rate for metastatic osteosarcoma remains less than 20 percent for the last 40 years. Tomoo Iwakuma, MD, PhD, is leading research focused on the elucidation of mechanisms underlying osteosarcoma progression and the discovery of novel drugs against this osteosarcoma. His laboratory has identified a lead compound that specifically killed canine and human osteosarcoma cells lacking the activity of the tumor suppressor p53, with minimal impact on non-tumor cells. Join us as we visit with Dr. Iwakuma about this promising research.
Publication Date
11-19-2018
Recommended Citation
Smith, Michael and Iwakuma, Tomoo, "Identifying Novel Drug Treatment Options for Pediatric Osteosarcoma" (2018). Transformational Pediatrics Podcast. 129.
https://scholarlyexchange.childrensmercy.org/transformational-peds_podcast/129
